This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.
* The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures
Participants must have a confirmed malignancy requiring stereotactic body radiation therapy. See specific disease site cohorts for more details.
Tumor size ≤ 7cm
Age 18 years of older.
ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
Specific exclusion requirements for each disease site with be covered in each specific cohort
History of allergic reactions attributed to gadolinium-based IV contrast.
Pregnant women are excluded from this study.
Severe claustrophobia or anxiety
19
Treatment groupsSee each treatment group below.